iSonea Announces Fully Underwritten Renounceable Rights Issue to Raise $4M • Renounceable Rights Issue to raise A$4 million from shareholders • Rights Issue is fully underwritten • Funds raised for development of the AirSonea™ and SonoSentry™ devices and the rollout of next generation AsthmaSense™ smart phone apps Melbourne, Australia and Severna Park, MD — September 27, 2012 - Medical technology company iSonea Limited (ASX: ISN; OTCQX: ISOAY) is pleased to announce the launch of a renounceable Rights Issue to raise $4 million to allow the Company to develop the AirSonea™ and SonoSentry™ devices and to rollout the next generation AsthmaSense™ smart phone apps. The Rights Issue is fully underwritten by leading Australian Stockbroker, Patersons, whose sub-underwriting commitments were strongly oversubscribed. Under the Rights Issue the shareholders will be able to subscribe for three new fully paid ordinary shares for every five shares held on 8 October 2012, at an issue price of A$0.05 per share. The maximum number of shares offered under the Rights Issue is 80,725,145. iSonea is pleased to offer the opportunity for existing shareholders to share in the next crucial phase of commercial development and preparation for launch for the AirSonea asthma monitoring system. iSonea CEO Michael J. Thomas said, “Having this Rights Issue fully underwritten demonstrates the market’s confidence in our new Board, our experienced management team, and the new strategic direction for the Company.”
ISN Price at posting:
5.0¢ Sentiment: None Disclosure: Not Held